BCNstocks (@BCNstocks) header
BCNstocks (@BCNstocks) profile picture
Joined November 2018
Photo by BCNstocks (@BCNstocks)Photo by BCNstocks (@BCNstocks)Photo by BCNstocks (@BCNstocks)Photo by BCNstocks (@BCNstocks)Photo by BCNstocks (@BCNstocks)Photo by BCNstocks (@BCNstocks)Photo by BCNstocks (@BCNstocks)Photo by BCNstocks (@BCNstocks)Photo by BCNstocks (@BCNstocks)Photo by BCNstocks (@BCNstocks)
$ADIA New Article. Some solid details in this 3 minute read. As always, do your own DD. This is a good place to start. teapawt.net/ResearchAllcap/status/…
$ADIA This article is part of our Weekly Deep Dive series — independently selected coverage focused on company structure, operations, and market positioning. This Article is not sponsored content. Follow for structured market coverage and weekly deep dives. allcapresearch.com/weekly-de…
1
1
2
123
$ADHC MONDAY PREP – APRIL 5, 2026 The April 1 announcement that GlucoGuard retained a global CRO for FDA-required patient studies (integrating Dexcom CGM tech) continues to build underlying strength. This is a major regulatory milestone for the AI-powered oral device targeting nocturnal hypoglycemia — clearing a key path toward Breakthrough Device Designation in a massive diabetes market with zero direct competition. After the strong volume reaction, shares pulled back to the ~$0.0010 level on profit-taking — creating what could be an attractive dip-buying opportunity ahead of next week’s expected PR updates in the multi-week rollout. Thin float micro-cap setup means fresh catalysts could drive a sharp rebound toward $0.0015 and higher. Regulatory progress + AI diabetes tech = real upside potential building. High risk / high reward speculative play. DYOR — not financial advice. Adding on the dip or watching for the next catalyst on $ADHC? Drop your thoughts 👇 #ADHC #GlucoGuard #DiabetesTech #OTC @SuperRobotGX
5
15
511
$ADHC WEEKEND WATCH – APRIL 4, 2026 GlucoGuard’s recent move to retain a global CRO for FDA patient studies (with Dexcom CGM integration) is a strong step forward. This multi-patient trial advances the AI-powered oral device targeting nocturnal hypoglycemia — positioning $ADHC closer to Breakthrough Device Designation in a massive diabetes market with zero direct competition. After pulling back to the $0.0010 area on light profit-taking, the thin float micro-cap ($2.5M market cap) looks primed for a rebound as the multi-week PR rollout continues next week. Strong volume on the April 1 news showed real interest — any fresh update could spark a solid move back toward $0.0015 and beyond. AI + diabetes tech with real regulatory momentum building. High risk / high reward speculative play with upside potential. DYOR — not financial advice. Bullish on $ADHC heading into next week or adding on this dip? Let’s hear it 👇 #ADHC #GlucoGuard #DiabetesTech #OTC @SuperRobotGX @ADHCMANAGEMENT
4
15
374
$ADHC MOMENTUM BUILDING POST-NEWS GlucoGuard just retained a global Contract Research Organization (CRO) to launch the FDA-required multi-patient studies — a major milestone. 🔹 Studies will integrate Dexcom ($DXCM) CGM tech for real-time glucose monitoring 🔹 Focused on proving safety & efficacy of the AI-powered oral device targeting nocturnal hypoglycemia 🔹 Path accelerating toward Breakthrough Device Designation in a massive diabetes market with zero direct competition The April 1 PR is sparking renewed interest. Traders watching for follow-up updates next week as the multi-week rollout continues. Thin float OTC name reacting on volume — still eyeing a move above $0.0015. AI + diabetes tech play with real FDA progress. High risk / high reward speculative name. Loading shares or sitting on the sidelines for $ADHC? Let me know 👇 #ADHC #GlucoGuard #DiabetesTech #OTC @SuperRobotGX @GlucoGuardSleep
5
13
285
$ADIA showing a sharp pullback after a strong run, now testing a key support zone near the recent lows (~$0.06–$0.08 range). Bounce attempt underway but still below prior consolidation. Watch: • Reclaim of $0.14–$0.16 = strength returning • Failure here = potential retest of lows Volume spike on selloff suggests caution — not a confirmed reversal yet. High risk / high reward OTC setup. Manage size accordingly.
2
4
88
BCNstocks retweeted
$ADIA Adia Nutrition showing real traction! 2025 revenue jumped to ~$700K (massive increase from prior year) while Adia Med advances its regenerative medicine pipeline: Autism stem cell study with UCF CARD actively recruiting (interventional phase starting soon) Final revised protocol submitted for AdiaVita lower back pain clinical study From stem cell therapies to regenerative aesthetics and supplements — building a diversified play in high-growth healthcare. Under-the-radar biotech with clinical + revenue momentum.
3
6
87
$ADIA News out yesterday was well received..closed up 29 percent.. News came out this morning. Adia Nutrition, Inc. Reports Strong Revenue Growth in 2025 Annual Report, Highlighting Transition to Regenerative Medicine and Full SEC Reporting Status otcmarkets.com/stock/ADIA/ne……
3
1
6
439
$ADHC A key component of the GlucoGuard study is the integration of Dexcom CGM technology, enabling precise, real-time glucose tracking before and after treatment. This directly aligns with FDA endpoint requirements and adds a strong layer of data reliability to the trial design.
This Post is from a suspended account. Learn more
3
1
10
1,383
$ADHC $DXCM News. American Diversified Holdings Operating Division GlucoGuard Retains Global Contract Research Organization (CRO) to Begin Patient Studies as Required by the FDA otcmarkets.com/stock/ADHC/ne…
3
6
198
$ADHC Patient studies begin. Big news for an OTC company. FDA approval one step closer as they begin their marketing campaign rollout.
5
1
10
1,684
This quoted post is unavailable.
2
9
207
BCNstocks retweeted
$ADHC News: American Diversified Holdings Operating Division GlucoGuard Retains Global Contract Research Organization (CRO) to Begin Patient Studies as Required by the FDA otcmarkets.com/stock/ADHC/ne…
4
8
115
$ADHC respecting a clean rising channel and continuing to print higher lows — trend still intact despite today’s pullback. Structure: • Consistent higher lows since late January • Riding the lower trendline support • Recent push into ~$0.0015 area before rejection Now testing mid-channel. Key levels: 👉 Hold $0.0011–$0.0012 = bullish structure intact 👉 Break below trendline = potential reset toward $0.0009 👉 Break above $0.0015 = continuation setup Narrative still centered on: • GlucoGuard (AI diabetes platform) • Dexcom integration angle • Broader health-tech + AI positioning Volume steady — watching for expansion on next move. High-risk OTC — trend is up, but needs confirmation on breakouts. #OTC #Stocks #ADHC
2
2
8
529
$ADHC GlucoGuard targets nocturnal hypoglycemia with an AI-powered system that continuously monitors glucose and automatically delivers it when levels drop—enabling real-time intervention and improved patient outcomes. allcapresearch.com/f/ai-powe…
1
1
6
343
$ADHC off to a strong start this morning. Could get interesting today!
$ADHC strong watch today! News confirmed. #AI #ADHC Universal Wellness AI uses AI to advance prevention, early detection, and personalized care through connected apps, algorithms, and bio-devices—enabling predictive insights and better health outcomes for longer, healthier lives
2
8
244
BCNstocks retweeted
This quoted post is unavailable.
6
10
318
BCNstocks retweeted
$ADHC New Article. American Diversified Holdings (OTC: ADHC): GlucoGuard and the Push Into AI-Driven Diabetes Care $DXCM #AI #Diabetes #Health #Wellness allcapresearch.com/f/ai-powe…
1
6
140
$ADHC expecting PR to hit on Wednesday, April 1st. #Diabetes #AI #GlucoGuard #ADHC
This quoted post is unavailable.
1
27